calithera
biosciences
announces
new
employment
inducement
grant
nasdaq
listing
rule
c
south
san
francisco
globe
newswire
calithera
biosciences
nasdaq
cala
clinical
stage
biotechnology
company
focused
discovering
developing
novel
small
molecule
drugs
treatment
cancer
diseases
today
announced
compensation
committee
company
board
directors
granted
one
new
employee
stock
option
purchase
aggregate
shares
calithera
common
stock
per
share
exercise
price
closing
trading
price
september
option
vests
september
balance
option
vests
series
successive
equal
monthly
installments
thereafter
granted
pursuant
calithera
biosciences
inducement
plan
inducement
plan
approved
calithera
board
directors
january
accordance
nasdaq
listing
rule
c
stock
option
also
ten
year
term
subject
terms
conditions
inducement
plan
stock
option
agreement
pursuant
option
granted
stock
option
granted
inducement
material
new
employee
entering
employment
calithera
accordance
nasdaq
listing
rule
c
calithera
calithera
biosciences
biopharmaceutical
company
pioneering
discovery
development
targeted
therapies
disrupt
cellular
metabolic
pathways
preferentially
block
tumor
cells
enhance
activity
driven
commitment
rigorous
science
passion
improving
lives
people
impacted
cancer
diseases
calithera
advancing
pipeline
oral
therapeutics
meaningfully
expand
treatment
options
available
patients
calithera
headquartered
south
san
francisco
california
information
calithera
please
visit
forward
looking
statements
statements
contained
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
words
may
expect
anticipate
estimate
intend
poised
similar
expressions
well
words
expressions
referencing
future
events
conditions
circumstances
intended
identify
statements
statements
include
related
safety
tolerability
efficacy
calithera
product
candidates
overall
advancement
calithera
product
candidates
clinical
trials
unmet
need
treatment
patients
advanced
disease
calithera
plans
continue
development
product
candidates
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
product
candidates
calithera
develops
may
progress
clinical
development
receive
required
regulatory
approvals
within
expected
timelines
addition
clinical
trials
may
confirm
safety
potency
product
characteristics
described
assumed
press
release
product
candidates
may
beneficial
patients
successfully
commercialized
failure
meet
expectations
respect
foregoing
matters
may
negative
effect
calithera
stock
price
additional
information
concerning
risk
factors
affecting
calithera
business
found
calithera
recent
quarterly
report
form
filed
securities
exchange
commission
periodic
filings
securities
exchange
commission
statements
guarantees
future
performance
speak
date
hereof
except
required
law
calithera
disclaims
obligation
update
statements
reflect
future
events
circumstances
source
calithera
biosciences
inc
contact
jennifer
mcnealey
ir
